DUBLIN – Shares in Gensight Biologics SA gained as much as 25% Monday as the company reported 96-week data from the phase III Rescue trial of its GS-010 gene therapy treatment for patients with Leber hereditary optical neuropathy (LHON) arising from the G11778A mutation in the mitochondrial gene encoding NADH dehydrogenase 4 (ND4).